Global Radiopharmaceuticals in Nuclear Medicine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 Bharat Book Bureau Provides the Trending Industry Research Report on“Global Radiopharmaceuticals in Nuclear Medicine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028”under Life Sciences Market Research Report. The report offers a collection of superior Market research, Market analysis, competitive intelligence and Market reports. Executive Summary The Radiopharmaceuticals in Nuclear Medicine Market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Radiopharmaceuticals in Nuclear Medicine market size is estimated to be worth US$ 4943.7 million in 2021 and is forecast to a readjusted size of USD 6857.2 million by 2028 with a CAGR of 4.8% during review period. Diagnostic Application accounting for % of the Radiopharmaceuticals in Nuclear Medicine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Diagnostic Radiopharmaceuticals segment is altered to a % CAGR between 2022 and 2028. Global key manufacturers of Radiopharmaceuticals in Nuclear Medicine include Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, and